logo-loader
NASDAQ:ESPR

Esperion Therapeutics Inc

Receive alerts
Market:
NASDAQ
Market Cap:
$1.07 billion
Price
38.66 USD
Change
0.23%
52 weeks high
76.98
52 weeks low
24.82

In brief

Esperion is the Lipid Management Company passionately committed to developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated LDL-C.

Bempedoic acid and the company's lead product candidate, the bempedoic acid / ezetimibe combination pill, are targeted therapies that have been shown to significantly lower elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies.